Skip to main content
. 2021 Nov 9;20:219. doi: 10.1186/s12933-021-01410-7

Table 3.

Correlations between changes in β-OHB, blood pressure and vascular parameters

Empa Δβ-OHB Placebo Δβ-OHB
Δ Resting peripheral systolic BP r = 0.458 r = − 0.336
p = 0.011 p = 0.203
Δ Resting peripheral diastolic BP r = 0.365 r = − 0.162
p = 0.047 p = 0.548
Δ Resting peripheral pulse pressure r = 0.471 r = − 0.087
p = 0.009 p = 0.749
Δ Central systolic BP r = 0.470 r = − 0.413
p = 0.009 p = 0.112
Δ Central pulse pressure r = 0.391 r = − 0.266
p = 0.033 p = 0.320
Δ Forward pulse pressure height r = 0.451 r = 0.086
p = 0.012 p = 0.752
Δ Resting pulse pressure height r = 0.217 r = − 0.342
p = 0.250 p = 0.194
Δ Systolic 24 h ambulatory BP r = 0.321 r = 0.141
p = 0.069 p = 0.630
Δ Diastolic 24 h ambulatory BP r = 0.516 r = 0.195
p = 0.002 p = 0.504
Δ Heart rate r = 0.188 r = 0.439
p = 0.320 p = 0.089

Δ: change between baseline and after 12 weeks of treatment, β-OHB: β-hydroxybutyrate; empa: empagliflozin; BP: blood pressure